The Pancreatic Cancer Early Detection (PRECEDE) Consortium, a beacon of hope in the global fight against pancreatic cancer, hosted its fifth annual meeting at the Cornell Tech Verizon Center on Roosevelt Island.
Global experts gather at Cornell Tech, advancing early detection and survival in pancreatic cancer fight
NEW YORK, NY / ACCESSWIRE / December 8, 2023 / The Pancreatic Cancer Early Detection (PRECEDE) Consortium, a beacon of hope in the global fight against pancreatic cancer, hosted its fifth annual meeting at the Cornell Tech Verizon Center on Roosevelt Island. This significant event, which took place on December 6th and 7th, marked a critical juncture in PRECEDE’s mission to dramatically improve pancreatic cancer survival rates through early detection and prevention.
Pancreatic cancer, known for its low survival rate and rapid progression, has long cast a shadow over countless lives. The five-year survival rate stands at a mere 12%. PRECEDE, with its groundbreaking approach and international collaboration, aims to revolutionize this statistic, targeting an ambitious increase to 50% within the next decade.
Over 50 leading academic medical centers from around the globe highlight PRECEDE’s remarkable growth and unwavering commitment. The consortium has now assembled the largest cohort of high-risk patients, supported by an unprecedented collection of longitudinal clinical data and biospecimens. This collaborative effort is not just a scientific endeavor; it’s a lifeline to millions at risk of this devastating disease.
“Early detection of pancreatic cancer is not just a medical challenge; it’s a promise of life,” said Diane Simeone, MD, Chair, at PRECEDE. “Our collaborative model, focusing on risk modeling, screening, and prevention, particularly for those with heritable risks, is a game-changer. We are not just conducting research; we are saving lives.”
Families and communities worldwide have felt the heart-wrenching impact of a disease that offers little warning and fewer options for treatment. PRECEDE’s work is a beacon of hope, shining a light on the possibility of a future where this cancer can be detected early and managed effectively.
As PRECEDE entered its fifth year, the consortium is witnessing exponential growth, both in its research capabilities and its potential to make a tangible difference. The collaboration, data sharing, and innovative approaches discussed and developed at the meeting are expected to usher in a new era in the fight against pancreatic cancer.
The PRECEDE Consortium’s work is a testament to the power of unity in the face of adversity. By bringing together the brightest minds and the most advanced resources, PRECEDE stands at the forefront of a movement that is not just about scientific discovery, but about giving patients and families hope, time, and a fighting chance against pancreatic cancer.
For more information about PRECEDE and its mission, please visit precedestudy.org
Supporting this critical research is Trovanow, a dedicated non-profit charity. Trovanow plays a vital role in funding and facilitating the groundbreaking work undertaken by PRECEDE. Contributions to Trovanow directly bolster the efforts to transform pancreatic cancer from a deadly disease to a manageable condition. Join this noble cause, visit trovanow.org and help support our efforts in making a significant difference in the lives of those affected by pancreatic cancer.
Contact Information
Ron Horvat
Executive Director
rhorvat@trovanow.org
Related Images
|
 |
SOURCE: PRECEDE
View the original press release on accesswire.com
